Azar Alex M II sold $10K of GH

Azar Alex M II sold 69 shares of Guardant Health, Inc. (GH) at $149.56 on 2026-11-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Azar Alex M II
Published Nov 17, 2026, 10:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 11:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

Because the transaction is a small open-market sale and explicitly pre-arranged, it typically does not warrant a fundamental repricing. The main trading relevance is sentiment monitoring for unusual clustering of insider sales.

02

Market read

Routine insider selling disclosure with limited expected price impact.

03

What to watch

The article does not disclose any buy-side offset, broader insider activity, or changes in operating outlook, limiting the signal beyond routine compliance.

Relevance 2/10Novelty 2/10Timing: filed 2026-11-17, transaction dated 2026-11-16

Background

The article is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc., reported by a director under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health director Azar Alex M II filed a Form 4 showing an open-market sale of 69 shares at $149.56 on 2026-11-16 under a 10b5-1 plan.

Expected impact

Likely limited impact; any reaction would be muted because the transaction is small and explicitly under a Rule 10b5-1 plan.

Evidence & confidence

The filing is a Form 4 insider transaction, not an earnings, guidance, or regulatory event. The article provides only a modest sale size and confirms it is pre-arranged via 10b5-1, which typically reduces interpretive signal.

Market effects

No clear sector read-through; this is company-specific insider trading with no operational or regulatory catalyst.

None.

None.

Counterpoint

Even 10b5-1 sales can coincide with periods of insider risk management, so traders may briefly watch for follow-on selling or other insider activity.

Key entities

  • Guardant Health, Inc.

    US-listed company subject of the Form 4 insider transaction disclosure.

  • Azar Alex M II

    Director who sold 69 shares on 2026-11-16 under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.